Petition Update — January 19, 2026 VYD2311 Trial Begins

Happy New Year, and thank you for continuing to stand with us — even in the face of so much global turmoil and uncertainty.

While 2025 has been difficult for many, hope persists — and progress continues.

It’s been a while since our last update.

We’ve contacted Health Canada and multiple elected officials. We’ve received no response. The silence has been deafening.

But scientific progress hasn’t stood still.

⸻

VYD2311: A New Monoclonal Antibody Moves to Phase 3

Invivyd has initiated the Phase 3 DECLARATION trial for VYD2311, a variant-resistant monoclonal antibody intended as a vaccine alternative for COVID-19 prevention.

This new antibody builds upon Pemgarda (Pemivibart), updated for broader protection against current and emerging variants. It’s designed to offer crucial protection for those who remain at risk — including the immunocompromised.

VYD2311 has also received Fast Track Designation from the U.S. FDA, signaling its potential to fill a critical gap in COVID-19 prevention.

🔬 Learn more:

Press Release — Trial Launch:

https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-initiation-declaration-clinical-trial-phase-3

Fast Track Designation:

https://investors.invivyd.com/news-releases/news-release-details/invivyd-earns-fast-track-designation-vyd2311-vaccine-alternative

Clinical Trial Listing:

https://www.clinicaltrials.gov/study/NCT07298434

⸻

Trial Eligibility: Not Just for High-Risk Groups

While our petition focuses on the immunocompromised, it’s worth noting that the DECLARATION trial is open to both high-risk and healthy individuals. This helps researchers assess how well VYD2311 works across a wide population.

If you or someone you know is interested, you may wish to inquire about participating in the trial.

But make no mistake: for the immunocompromised in Canada, there is still no access to Pemgarda or any variant-resistant monoclonal antibody. Even as science advances, policy continues to lag behind.

⸻

We’re Still Here. Still Fighting.

This petition remains active because our work isn’t finished.

We continue to push for access to life-saving tools for the most vulnerable.

Every voice matters. Every share helps. We won’t stop until protection is a right — not a privilege.

Thank you for standing with us.

Sign & share:

https://www.change.org/p/protect-vulnerable-canadians-access-to-covid-19-monoclonal-antibodies-long-covid-trials

— Rowan